Relvar Ellipta Overdosage

Symptoms and signs: There are no data available from clinical trials on overdose with Fluticasone furoate + Vilanterol (as trifenatate) (Relvar Ellipta).
An overdose of Fluticasone furoate + Vilanterol (as trifenatate) (Relvar Ellipta) may produce signs and symptoms due to the individual components' actions, including those seen with overdose of other beta₂-agonists and consistent with the known inhaled corticosteroid class effects (see Precautions).
Treatment: There is no specific treatment for an overdose with Fluticasone furoate + Vilanterol (as trifenatate) (Relvar Ellipta). If overdose occurs, the patient should be treated supportively with appropriate monitoring as necessary.
Cardioselective beta-blockade should only be considered for profound vilanterol overdose effects that are clinically concerning and unresponsive to supportive measures. Cardioselective beta-blocking drugs should be used with caution in patients with a history of bronchospasm.
Further management should be as clinically indicated or as recommended by the national poisons centre, where available.